Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Oral Cavity Cancer Clinical Trials

A listing of Oral Cavity Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (76) clinical trials

The Relation of Microtubule-Associated Protein 2 and Cell Migration

Betel quid chewing has been shown to have intimate correlation with oral cancer. In Taiwan, the incidence of oral cancer is the fourth most common malignancy in male and in fact, 90% of which has been linked to betel quid chewing. The predisposing factors in oral cancers between the western ...

Phase N/A

Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography

Diagnosis of oral precancers and cancers using optic coherence tomography

Phase

Expression of VEGF-C and VEGF-CR in Oral Cancers and Premalignant Lesions

The role of vascular endothelial growth factor-C (VEGF-C) and its receptors induced lymphangiogenesis and host inflammatory responses on the carcinogenesis of oral cancers and premalignant lesions

Phase N/A

Expression of Hypoxia-Inducible Factor- in Oral Precancers and Cancers

Expression of hypoxia-inducible factor-α in oral precancers and cancers

Phase N/A

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied. The purpose of this study is to evaluate effectiveness ...

Phase

Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies

Objectives Primary Objectives: For Arms D-G, to establish the safety, tolerability, and dose-limiting toxicities (DLTs) of different treatment combinations of avelumab when administered in combination with checkpoint agonist(s) with or without radiation, or radiation and cisplatin in patients with limited, locally advanced or metastatic solid tumors in order to estimate ...

Phase

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

PHASE I: Participants will be enrolled sequentially and treated at Dose Level 1, or Dose Level -1, every 2 weeks for 12 cycles or until discontinuation. Each cycle is 4 weeks. Cetuximab is given alone in lead-in period at Day -14 before Cycle 1 only. In all subsequent doses starting ...

Phase

Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification HER2 Mutation/Amplification HER3/4 Mutation or KRAS Mutation

Objectives Primary Objectives: To evaluate the safety and tolerability of neratinib when combined with one of the following agents Arm 1: Everolimus (mTOR inhibitor) Arm 2: Palbociclib (CDK 4/6 inhibitor) Arm 3: Trametinib (MEK inhibitor) To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of neratinib combination therapy. ...

Phase

Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to a study group based on when you joined the study. Up to 5 groups of 3-6 participants will be enrolled in the dose escalation part of the study. Up to ...

Phase

ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment

PRIMARY OBJECTIVES: I. To determine whether 14-21 days of treatment with ACTOplus met XR will result in a decrease in proliferation index (Ki-67) expression in oral cavity/oropharyngeal tumor tissue as compared to placebo. SECONDARY OBJECTIVES: I. Compare differences in proliferation index (Ki-67) expression from baseline to post-exposure in visually normal ...

Phase